Blood advances
Journal
Overview
publication venue for
-
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.
2020
-
Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLL.
2025
-
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry..
9.
2025
-
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia..
9.
2025
-
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study..
9.
2025
-
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
2025
-
Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features..
9.
2025
-
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.
2025
-
IDCH: is it now determined?.
9.
2025
-
High Pulmonary Hypertension Risk by Echocardiogram Shortens Survival in Polycythemia Vera.
2024
-
Deficit accumulation frailty index (DAFI) and treatment tolerability in AML: Data from CALGB 11001 and 11002 (Alliance).
2024
-
Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium.
2024
-
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy..
8.
2024
-
Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function..
8.
2024
-
What is in a name: defining pediatric refractory ITP..
8.
2024
-
Outcomes in Children with Provoked Venous Thrombosis and Antiphospholipid Antibodies: Findings from the Kids-DOTT Trial.
2024
-
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft versus host disease.
2024
-
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts..
8.
2024
-
Evaluating Lab-Based Eligibility Criteria by Race/Ethnicity in Clinical Trials of Diffuse Large B-Cell Lymphoma.
2024
-
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib..
8.
2024
-
Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma.
2024
-
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis..
8.
2024
-
Defining Primary Refractory Large B-cell Lymphoma.
2024
-
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
2024
-
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.
2024
-
An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL.
2024
-
Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101.
2024
-
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in T- and/or NK-cell lymphoma patients.
2024
-
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database..
8.
2024
-
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma..
8.
2024
-
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
2024
-
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes..
8.
2024
-
Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components.
2024
-
Racial/ ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation.
2024
-
Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.
2024
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML..
8.
2024
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
2024
-
Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes in ELN Favorable Risk NPM1-mutated AML.
2024
-
High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer.
2024
-
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type..
7.
2023
-
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms..
7.
2023
-
Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant..
7.
2023
-
Gender disparities in allograft access due to HLA-sensitization in multiparous women.
2023
-
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies..
7.
2023
-
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma..
7.
2023
-
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression..
7.
2023
-
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
2023
-
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories..
7.
2023
-
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis..
7.
2023
-
Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT..
7.
2023
-
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma..
7.
2023
-
Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma.
2023
-
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation..
7.
2023
-
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303..
7.
2023
-
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia..
7.
2023
-
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia..
7.
2023
-
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma..
7.
2023
-
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy..
7.
2023
-
Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia..
7.
2023
-
Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients..
7.
2023
-
Clonal hematopoiesis in survivors of childhood cancer..
7.
2023
-
Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation..
7.
2023
-
PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma.
2023
-
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma..
7.
2023
-
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates..
7.
2023
-
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
2023
-
How I read an article that uses machine learning methods.
2023
-
Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome.
2023
-
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells..
7.
2023
-
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia..
7.
2023
-
Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma.
2023
-
Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.
2023
-
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults..
6.
2022
-
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS..
6.
2022
-
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models.
2022
-
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML.
2022
-
Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones.
2022
-
Racial disparities in access to alternative donor allografts persist in the era of "donors for all"..
6.
2022
-
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
2022
-
Patient perspectives on testing for clonal hematopoiesis of indeterminate potential.
2022
-
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy..
6.
2022
-
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma..
6.
2022
-
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
2022
-
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen..
6.
2022
-
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment..
6.
2022
-
Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy..
6.
2022
-
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients
2022
-
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
2022
-
A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome..
6.
2022
-
Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness..
6.
2022
-
Myb drives B-cell neoplasms and myeloid malignancies in vivo..
6.
2022
-
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey..
6.
2022
-
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn..
6.
2022
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML..
6.
2022
-
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML..
6.
2022
-
Geriatric assessment for older adults receiving less intensive therapy for acute myeloid leukemia: Report of CALGB 361101.
2022
-
Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency..
6.
2022
-
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT..
6.
2022
-
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
2022
-
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation..
6.
2022
-
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia..
6.
2022
-
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML..
6.
2022
-
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma..
5.
2021
-
ALCAM-EGFR interaction regulates myelomagenesis..
5.
2021
-
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies..
5.
2021
-
PD-1 inhibition in advanced myeloproliferative neoplasms..
5.
2021
-
Restriction of HIV-1 infection in sickle cell trait..
5.
2021
-
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma..
5.
2021
-
Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes.
2021
-
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome..
5.
2021
-
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease..
5.
2021
-
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS..
5.
2021
-
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells..
5.
2021
-
Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy.
2021
-
Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications..
5.
2021
-
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis..
5.
2021
-
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation..
5.
2021
-
Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML..
5.
2021
-
Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis..
5.
2021
-
ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML..
5.
2021
-
Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML..
5.
2021
-
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML..
5.
2021
-
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19..
5.
2021
-
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses..
5.
2021
-
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma..
5.
2021
-
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant..
5.
2021
-
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults..
4.
2020
-
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease..
4.
2020
-
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub..
4.
2020
-
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis..
4.
2020
-
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development..
4.
2020
-
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma..
4.
2020
-
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response..
4.
2020
-
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes..
4.
2020
-
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase..
4.
2020
-
HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation..
4.
2020
-
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma..
4.
2020
-
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs..
4.
2020
-
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies..
4.
2020
-
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality..
4.
2020
-
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report..
4.
2020
-
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML..
4.
2020
-
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure..
4.
2020
-
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms..
4.
2020
-
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML..
4.
2020
-
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia..
4.
2020
-
CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma..
4.
2020
-
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA..
4.
2020
-
Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia..
4.
2020
-
Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk..
4.
2020
-
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management..
4.
2020
-
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation..
4.
2020
-
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL..
4.
2020
-
Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin..
4.
2020
-
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents..
3.
2019
-
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes..
3.
2019
-
Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor..
3.
2019
-
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells..
3.
2019
-
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants..
3.
2019
-
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma..
3.
2019
-
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia..
3.
2019
-
Challenges and approaches to implementing master/basket trials in oncology..
3.
2019
-
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition..
3.
2019
-
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning..
3.
2019
-
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies..
3.
2019
-
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission..
3.
2019
-
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL..
3.
2019
-
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia..
3.
2019
-
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib..
3.
2019
-
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms..
3.
2019
-
CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking..
3.
2019
-
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease..
3.
2019
-
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis..
3.
2019
-
Targeting CD47 in Sézary syndrome with SIRPαFc..
3.
2019
-
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma..
3.
2019
-
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma..
3.
2019
-
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults..
3.
2019
-
B-cell tumor development in Tet2-deficient mice..
2.
2019
-
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)..
2.
2018
-
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas..
2.
2018
-
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms..
2.
2018
-
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation..
2.
2018
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia..
2.
2018
-
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802..
2.
2018
-
In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance..
2.
2018
-
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort..
2.
2018
-
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission..
2.
2018
-
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia..
2.
2018
-
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort..
2.
2018
-
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis..
2.
2018
-
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma..
2.
2018
-
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity..
2.
2018
-
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia..
2.
2018
-
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles..
2.
2018
-
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy..
1.
2017
-
Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review..
1.
2017
-
The clinical spectrum of Erdheim-Chester disease: an observational cohort study..
1.
2017
-
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma..
1.
2016
-
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment..
1.
2016
-
Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma..
3.
2019
-
Inaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and health care delivery.
2023
-
Under AI's lens: spotting mutations visually..
8.
2024
-
Optimizing liver health before and after gene therapy for hemophilia A.
2024
-
Retrospective characterization of nodal marginal zone lymphoma.
2023
-
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
2018
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)